RETINALGENIX TECHNOLOGIES INC.

Highlights RetinalGenix Technologies Inc.

Equities

RTGN

US76133Y1055

Market Closed - OTC Markets Other stock markets 12:47:02 2024-02-22 pm EST			5-day change	1st Jan Change
3.5 ^USD	+12.90%		-.--%	+13.27%

Apr. 01	RetinalGenix Technologies Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Feb. 09	RetinalGenix Technologies Inc. announced that it has received $4.65 million in funding	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

RetinalGenix Technologies Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 01	CI
RetinalGeniX?? Technologies Inc. Contracts with Medsan, Inc. to Provide Diagnostic Testing Services for Its Institutional Review Board to Conduct a Study to Personalize Medical Evaluations for Patients Receiving Treatment for Wet Macular Degeneration	Dec. 26	CI
RetinalGenix Technologies Inc. Appoints Stephen Tannenbaum to the Business Advisory Board	Nov. 28	CI
RetinalGenix Technologies Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
RetinalGeniX Technologies Inc. Announces the Submission of Two Provisional Patent Applications for Investigational Therapeutic Drugs	Nov. 09	CI
RetinalGeniX Contracts With Avania CRO to Provide Guidance for Interactions With FDA on Development of Two Drug Therapies and the RetinalCam? Image Visualization Device	Nov. 08	CI
RetinalGeniX Technologies Inc. Announces Institutional Review Board Approves to Conduct Study to Personalize Medical Evaluations for Patients Receiving Treatment for Wet Macular Degeneration	23-10-30	CI
RetinalGenix Technologies Inc. Appoints Fred Chasalow to the Medical Advisory Board of DNA-GPS	23-08-28	CI
RetinalGenix Technologies Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
RetinalGenix Technologies Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-18	CI
RetinalGenix Technologies Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-31	CI
RetinalGenix Technologies Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-17	CI
RetinalGenix Technologies Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-19	CI
RetinalGenix Technologies Inc. acquired DNA/GPS Inc. from Lawrence Perich for $14 million.	22-07-05	CI
RetinalGenix Technologies Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-13	CI
RetinalGenix Technologies Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-15	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.

BENEFIT NOW